| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
URGN Stock Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.
UroGen Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.32 |
| 52 Week High | US$12.63 |
| 52 Week Low | US$4.85 |
| Beta | 0.93 |
| 1 Month Change | -30.44% |
| 3 Month Change | 11.68% |
| 1 Year Change | -31.18% |
| 3 Year Change | -73.65% |
| 5 Year Change | -78.45% |
| Change since IPO | -40.49% |
Recent News & Updates
Recent updates
UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09
We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?
Jun 14What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates
May 18What Type Of Returns Would UroGen Pharma's(NASDAQ:URGN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15We Think UroGen Pharma (NASDAQ:URGN) Needs To Drive Business Growth Carefully
Feb 17Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term
Jan 27
How Much Of UroGen Pharma Ltd. (NASDAQ:URGN) Do Insiders Own?
Jan 06President Elizabeth Barrett Just Bought 4.6% More Shares In UroGen Pharma Ltd. (NASDAQ:URGN)
Dec 16UroGen Pharma's(NASDAQ:URGN) Share Price Is Down 50% Over The Past Three Years.
Dec 08Shareholder Returns
| URGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.5% | -1.0% | -0.9% |
| 1Y | -31.2% | -15.2% | -18.9% |
Return vs Industry: URGN underperformed the US Biotechs industry which returned -16.1% over the past year.
Return vs Market: URGN underperformed the US Market which returned -20.5% over the past year.
Price Volatility
| URGN volatility | |
|---|---|
| URGN Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: URGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: URGN's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 195 | Liz Barrett | https://www.urogen.com |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
UroGen Pharma Ltd. Fundamentals Summary
| URGN fundamental statistics | |
|---|---|
| Market Cap | US$192.11m |
| Earnings (TTM) | -US$109.37m |
| Revenue (TTM) | US$62.44m |
3.1x
P/S Ratio-1.8x
P/E RatioIs URGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| URGN income statement (TTM) | |
|---|---|
| Revenue | US$62.44m |
| Cost of Revenue | US$6.98m |
| Gross Profit | US$55.46m |
| Other Expenses | US$164.83m |
| Earnings | -US$109.37m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.74 |
| Gross Margin | 88.82% |
| Net Profit Margin | -175.16% |
| Debt/Equity Ratio | -113.6% |
How did URGN perform over the long term?
See historical performance and comparison